{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T09:49:12Z","timestamp":1767260952577,"version":"3.41.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK089507","R01AI101307","R01HL113382","U M1HL119073"],"award-info":[{"award-number":["P30DK089507","R01AI101307","R01HL113382","U M1HL119073"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jcf.2023.05.014","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T11:26:33Z","timestamp":1685964393000},"page":"669-673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potential implicit bias in attribution of adverse events in randomized controlled trials in cystic fibrosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Ranjani","family":"Somayaji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7091-5669","authenticated-orcid":false,"given":"Madeline E.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-4165","authenticated-orcid":false,"given":"Tijana","family":"Milinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-368X","authenticated-orcid":false,"given":"Kathleen J.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie W.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonya","family":"Heltshe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umer","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"0","key":"10.1016\/j.jcf.2023.05.014_bib0001","article-title":"Interdisciplinary safety evaluation and quantitative safety monitoring: introduction to a series of papers","volume":"0","author":"Seltzer","year":"2019","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"10.1016\/j.jcf.2023.05.014_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomized controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"issue":"22","key":"10.1016\/j.jcf.2023.05.014_bib0003","first-page":"00130","article-title":"Immune-related adverse events in older adults: data mining of the FDA adverse event reporting system","volume":"31","author":"Chen","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"13","key":"10.1016\/j.jcf.2023.05.014_bib0004","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcf.2023.05.014_bib0005","unstructured":"IND application reporting: safety reports. Available at: https:\/\/www.fda.gov\/drugs\/investigational-new-drug-ind-application\/ind-application-reporting-safety-reports, Accessed on Mar 1, 2022. 2021."},{"issue":"6","key":"10.1016\/j.jcf.2023.05.014_bib0006","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cct.2006.06.001","article-title":"Respiratory adverse event profiles in cystic fibrossi placebo subjects in short- and long-term inhaled therapy trials","volume":"27","author":"Sucharew","year":"2006","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jcf.2023.05.014_bib0007","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jcf.2021.02.013","article-title":"Rates of adverse and serious adverse events in children with cystic fibrosis","volume":"20","author":"Pittman","year":"2021","journal-title":"Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society"},{"issue":"2","key":"10.1016\/j.jcf.2023.05.014_bib0008","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.cct.2012.11.005","article-title":"Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials","volume":"34","author":"Mayer-Hamblett","year":"2013","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"10.1016\/j.jcf.2023.05.014_bib0009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcf.2006.05.012","article-title":"Laboratory parameter profiles among patients with cystic fibrosis","volume":"6","author":"Goss","year":"2007","journal-title":"Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society"},{"key":"10.1016\/j.jcf.2023.05.014_bib0010","unstructured":"Common Toxicity Criteria for Adverse Events (CTCAE) v5.0. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50, Accessed on March 4, 2022. 2017."},{"key":"10.1016\/j.jcf.2023.05.014_bib0011","unstructured":"Guidance for Industry and Investigators - Safety Reporting Requirements for INDs and BA\/BE studies. Available at: https:\/\/www.fda.gov\/files\/drugs\/published\/Safety-Reporting-Requirements-for-INDs-%28Investigational-New-Drug-Applications%29-and-BA-BE-%28Bioavailability-Bioequivalence%29-Studies.pdf, Accessed Mar 2, 2022. 2012."},{"key":"10.1016\/j.jcf.2023.05.014_bib0012","unstructured":"NIH Policy and guidelines on the inclusion of women and minorities as subjects in clinical research. Available at: https:\/\/grants.nih.gov\/policy\/inclusion\/women-and-minorities\/guidelines.htm#:\u223c:text=It%20is%20the%20policy%20of,that%20inclusion%20is%20inappropriate%20with, Accessed on June 30, 2022. 2017."},{"key":"10.1016\/j.jcf.2023.05.014_bib0013","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/thoraxjnl-2012-202550","article-title":"Progress in cystic fibrosis and the CF Therapeutics Development Network","volume":"67","author":"Rowe","year":"2012","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.jcf.2023.05.014_bib0014","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jcf.2023.05.014_bib0015","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2023.05.014_bib0016","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jcf.2023.05.014_bib0017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcf.2014.08.008","article-title":"Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial","volume":"14","author":"Conrad","year":"2014","journal-title":"Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.014_bib0018","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Diff"},{"key":"10.1016\/j.jcf.2023.05.014_bib0019","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/d41586-020-02110-0","article-title":"The gender gap in cystic fibrosis","volume":"583","author":"Healey","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jcf.2023.05.014_bib0020","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/oxfordjournals.aje.a009172","article-title":"Gender gap in cystic fibrosis mortality","volume":"45","author":"Rosenfeld","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jcf.2023.05.014_bib0021","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1089\/jwh.2014.4985","article-title":"Gender differences in outcomes of patients with cystic fibrossi","volume":"23","author":"Harness-Brumley","year":"2014","journal-title":"J Women's Health (Larchmt)"},{"issue":"2","key":"10.1016\/j.jcf.2023.05.014_bib0022","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Resp Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2023.05.014_bib0023","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00042560-200008010-00003","article-title":"Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The AIDS clinical Trials Group 175 Team","volume":"24","author":"Currier","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcf.2023.05.014_bib0024","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.prrv.2008.04.002","article-title":"Genetic and non-genetic determinants of outcomes in cystic fibrosis","volume":"10","author":"Wolfenden","year":"2009","journal-title":"Pediatr Respir Rev"},{"key":"10.1016\/j.jcf.2023.05.014_bib0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/aje\/kwf014","article-title":"Delayed diagnosis of US females with cystic fibrosis","volume":"156","author":"Lai","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jcf.2023.05.014_bib0026","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jcf.2021.05.012","article-title":"Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations","volume":"20","author":"Montemayor","year":"2021","journal-title":"Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society"},{"issue":"163","key":"10.1016\/j.jcf.2023.05.014_bib0027","article-title":"Just breathe: a review of sex and gender in chronic lung disease","volume":"31","author":"Somayaji","year":"2022","journal-title":"Eur Respir J"},{"issue":"24","key":"10.1016\/j.jcf.2023.05.014_bib0028","article-title":"The impact of sex and gender on immunotherapy outcomes","volume":"11","author":"Klein","year":"2020","journal-title":"Biology Sex Diff"},{"issue":"11","key":"10.1016\/j.jcf.2023.05.014_bib0029","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3390\/vaccines9111322","article-title":"A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials","volume":"9","author":"Heidari","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.jcf.2023.05.014_bib0030","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/jgs.15020","article-title":"Systematic Review of Sex-Specific Reporting of Data: cholinesterase Inhibitor Example","volume":"65","author":"Mehta","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"7299","key":"10.1016\/j.jcf.2023.05.014_bib0031","first-page":"669","article-title":"Putting gender on the agenda","volume":"465","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2023.05.014_bib0032","series-title":"Handbook of experimental pharmacology","first-page":"3","article-title":"Sex and gender differences in clinical medicine","year":"2012"},{"issue":"288","key":"10.1016\/j.jcf.2023.05.014_bib0033","article-title":"Statistical methods for the analysis of adverse event data in randomized controlled trials: a scoping review and taxonomy","volume":"20","author":"Phillips","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jcf.2023.05.014_bib0034","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctrv.2019.04.004","article-title":"Improving attribution of adverse events in oncology clinical trials","volume":"76","author":"George","year":"2019","journal-title":"Cancer Treat Rev"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:33:47Z","timestamp":1751582027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323001443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1569199323001443"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.05.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"type":"print","value":"1569-1993"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential implicit bias in attribution of adverse events in randomized controlled trials in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}